ArticleLasers in medical science2025
Comparative efficacy of 450 nm blue-laser vaporization versus transurethral plasma kinetic enucleation of the prostate (TUPKEP) for benign prostatic hyperplasia in high-risk elderly patients: a focus on safety, efficacy, and sexual function preservation.
Article in Lasers in medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of blue laser vaporization of the prostate for benign prostatic hyperplasia: a systematic review and meta-analysis.The Canadian journal of urology · 2026Pooled it
- 450-nm blue laser vaporizationversustransurethral resection of the prostate for benign prostatic hyperplasia: a retrospective comparative study.The Canadian journal of urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveTo explore the clinical efficacy, safety, and potential value for preserving sexual function of the 450 nm advanced blue-laser device in the treatment of high - risk and elderly patients with benign prostatic hyperplasia (BPH).
methodsAnalysis was conducted on 161 elderly and high-risk patients with BPH who underwent surgical treatment. They were divided into the blue-lasergroup (77 cases) and the Transurethral Plasma Kinetic Enucleation of the Prostate (TUPKEP) (84 cases). The general data of the patients in both groups were collected, including age, TPSA, prostate volume, and comorbidities. Subsequently, intraoperative and postoperative indicators of the two groups were compared, including Qmax, IPSS, QoL scores before and after treatment, and complications.
resultsThe perioperative indicators of the patients in the 450 nm blue-lasergroup, namely the operation time and intraoperative blood loss, were 40.70 ± 15.44 min and 22.74 ± 19.98 ml, respectively, which were significantly lower than those of the TUPKEP group (81.61 ± 33.50 min and 65.45 ± 70.87 ml). The overall incidence of complications in the TUPKEP group was higher than that in the 450 nm blue-laser group, mainly manifested in transient urinary incontinence, sexual function, etc. The IIEF-5 score of the laser group at 3 months after surgery was significantly higher than that of the plasma enucleation group (17.04 ± 2.01). There was no significant difference in the comparison of Qmax, IPSS score, and QoL between the two groups at 3 months after surgery (P > 0.05).
conclusionThe 450 nm blue-laser vaporization for the treatment of high-risk BPH has advantages such as convenient operation, definite curative effect, and fewer complications.
Indexed as
Identifiers
40549059What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.